Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.23.00752 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reply to Z.R. McCaw et al.
J Clin Oncol
October 2023
Ursula A. Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA; Domenica Lorusso, MD, Fondazione Policlinico Universitario A. Gemelli, IRCCS and Catholic University of Sacred Heart, Rome, Italy; Ana Oaknin, MD, PhD, Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Sandro Pignata, MD, Istituto Nazionale Tumori di Napoli Fondazione G Pascale IRCCS, Naples, Italy; Andrew Dean, MD, WA Medical Oncology St John of God Subiaco Hospital, Subiaco, WA, Australia; Hannelore Denys, MD, PhD, Ghent University Hospital, Ghent, Belgium; Nicoletta Colombo, MD, European Institute of Oncology IRCCS, Milan, Italy and University of Milan-Bicocca, Milan, Italy; Toon Van Gorp, MD, University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium; Jason A. Konner, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Margarita Romeo Marin, MD, Institut Català d'Oncologia, Badalona, Spain; Philipp Harter, MD, Ev. Kliniken Essen-Mitte, Essen, Germany; Conleth G. Murphy, MD, Bon Secours Hospital and Cancer Trials, Cork, Ireland; Jiuzhou Wang, PhD; Elizabeth Noble, BS; Brooke Esteves, BS; and Michael Method, MD, ImmunoGen Inc, Waltham, MA; and Robert L. Coleman, MD, US Oncology Research, Texas Oncology, The Woodlands, TX.
Reply to Z.R. McCaw et al.
J Clin Oncol
September 2023
Jason E. Farrar, MD, Arkansas Children's Research Institute and Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR; Megan Othus, PhD, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Yi-Cheng Wang, MS, Children's Oncology Group, Monrovia, CA; Todd A. Alonzo, PhD, Children's Oncology Group, Monrovia, CA, Department of Population and Public Health Sciences, University of Southern California, Los Angeles, CA; and Soheil Meshinchi, MD, PhD, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, Department of Pediatrics, University of Washington, Seattle, WA.
Reply to Z.R. McCaw et al.
J Clin Oncol
February 2023
Hope S. Rugo, MD, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Gerardo A. Umanzor, MD, Centro Oncológico Integral With DEMEDICA, San Pedro Sula, Honduras; and Min-Fun R. Kwan, MBBS, MRCP, and David L. Cutler, MD, Athenex, Inc, Buffalo, NY.
Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.
Eur Urol
January 2021
Institut de Cancérologie Gustave Roussy, University of Paris, Villejuif, France. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!